Article
RSS feed >

The US Oncology Network and US Oncology Research affiliated physicians showcase clinical study results from more than 60 abstracts during ASCO Annual Meeting

Areas of research include immuno-oncology, use of pathways and value-based care, bladder cancer, lung cancer, blood cancers and more

The Woodlands, Texas (May 27, 2015) – Lead investigators affiliated withThe US Oncology Network and US Oncology Research will showcase detailed findings from more than 60 clinical trials at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 29-June 2 at McCormick Place in Chicago. These data presentations cover novel approaches to numerous types of cancer specialties including breast, bladder, blood and lung cancers as well as promising immunotherapy research.

“The robust collection of clinical research findings from physicians affiliated with The US Oncology Network and US Oncology Research, and being presented at the 51st ASCO Annual Meeting, exemplify the contributions being made to the future of cancer care by community oncologists, ” said Michael Seiden, MD, PhD, chief medical officer for The US Oncology Network and US Oncology Research. “We are proud of the work being done by the more than 900 experienced investigators affiliated with US Oncology Research. They are committed to testing these promising therapies through clinical trials in communities across the United States. In the past 23 years, we have been involved in the study of more than 300 investigational cancer therapies and helped bring more than 50 therapeutic treatments to market through participation in pivotal registration trials. These efforts are a testament to our commitment to developing novel therapies that improve the quality of care, and to the role of the community oncologist in our collective fight against cancer.” 

Nicholas Vogelzang, M.D., medical oncologist and cancer researcher with Comprehensive Cancer Centers of Nevada (CCCN), medical director of the US Oncology Research Executive Committee and Chair of the US Oncology Research Genitourinary Program, along with Fadi Braiteh, M.D., oncologist with CCCN and investigator with US Oncology Research, co-authored a trial study titled, “A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC).” This oral presentation will occur on Monday, June 1 from 9:57 AM to 10:09 AM Central Daylight Time (CDT) in E Arie Crown Theater as part of a larger session focused on Genitourinary (Nonprostate) Cancer. CCCN is a practice in The US Oncology Network.

“The oral presentation builds on the paper published last year in Nature,” said Dr. Vogelzang. “Our group of investigators, led by Dr. Thomas Powles from the Royal Marsden in London, originally reported on 67 patients with advanced bladder cancer treated with an antibody against PDL-1 developed by the Roche/Genentech scientists and clinicians. That paper reported a significant benefit in patients and stimulated considerable excitement world-wide. This year’s presentation provides an update on this experience to include 92 patients. The antibody, MPDL3280A, has considerable promise in treating patients with a heretofore incurable disease.”

Alex Spira, MD, PhD, FACP, medical oncologist with Virginia Cancer Specialists (VCS) and investigator with US Oncology Research, will be presenting findings in an oral presentation titled “Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).” The oral presentation will occur Sunday, May 31 from 4:30 PM to 4:42 PM CDT in E Hall D1. VCS is a practice in The US Oncology Network.

Novel approaches and diagnostics are also being discussed during the conference. Dr. Braiteh co-authored a trial study on this topic titled, “Successful Implementation of a Novel Trial Model - The Signature Program.” The oral presentation will occur on Monday, June 1 from 9:50 AM to 10:05 AM CDT in E Hall D and is part of the clinical science symposium, “New Diagnostics: When Actionable Is Objectionable.”

For the complete list of US Oncology Research affiliated studies being featured at ASCO click here.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials. US Oncology Research serves nearly 60 research sites and approximately 160 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 60,000 patients in more than 1,400 trials since inception in 1992 and have played a role in more than 50 FDA-approved cancer therapies, nearly one-third of all cancer therapies approved by the FDA to date. For more information call (800) 482-6700 or visit www.usoncology.com/oncologists.

About The US Oncology Network

The US Oncology Network is one of the nation’s largest networks of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.

Media Contact

Claire Crye
(281) 825-9927

###